Could a diabetes pill boost heart and muscle health in kidney patients?
NCT ID NCT07060417
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study will test whether empagliflozin (Jardiance), a drug already used for diabetes, can improve blood vessel health and exercise tolerance in 52 veterans with non-diabetic chronic kidney disease. Participants will take either the drug or a placebo for a period, and researchers will measure changes in artery function and leg blood flow. The goal is to see if this medication offers benefits beyond blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin (Jardiance)
- What this could lead to
- If successful, this could show that empagliflozin helps protect blood vessels and improve physical function in people with chronic kidney disease who do not have diabetes.
- What could go wrong
- This is a small, early-stage trial with only 52 participants, so results may not apply to everyone. It is also testing effects on blood vessel function rather than hard outcomes like kidney failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-DIABETIC CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.